CATALAYER NEWS
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER – Company Announcement - FT.com - Financial Times
Source: Financial Times · 2026-10-24
Full article text is available in the Catalayer news terminal.
MORE FROM FINANCIAL TIMES
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-muta
2026-10-25
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ mo
2026-10-25
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progressi
2026-10-25
Ping An Highlights Green Development Initiatives at International Communication Seminar in Shenzhen Ahead of APEC 2026 –
2026-10-25
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC - Financial Tim
2026-10-25
RELATED MARKETS
Prediction Markets